Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G-FLIP + Mitomycin C in advanced pancreatic cancer
NCT06233877Phase 2Not yet recruiting
- Sponsor
- Hirschfeld Oncology
- Start
- Mar 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mitomycin c in pancreatic adenocarcinoma (PDAC), sponsored by Hirschfeld Oncology. Primary endpoints: Overall Survival at 5 years and Response Rate at 5 years. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
mitomycin c
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06233877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06233877.